Search the Newsreel

Bristow Group: Q2 Earnings Snapshot

Bristow Completes $105 Million Berry Aviation Acquisition

Bristow Group (VTOL) Stock Still Looks Reasonable On Earnings Power

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

BioNTech Aktie: BNT327 mit Bristol Myers Squibb

Briscoe's Stock Looks Expensive Despite Sales Resilience -- Market Talk

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Jim Cramer expressed skepticism regarding the rumored $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, calling it a potential "fake out" and suggesting BMY needs assistance. The Financial Times reported ongoing discussions, which could lead to a cash and stock deal, combining AstraZeneca's …

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

The article argues that a potential merger between AstraZeneca and Bristol Myers Squibb, valued at nearly $400 billion, would be a disaster. It highlights severe regulatory concerns due to significant portfolio overlaps, potential pipeline disruptions, and massive job losses as key reasons against such …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

New Zealand Shares Rise; Briscoe Group's Fiscal Q2 Sales Increase

Earnings To Watch: Bristow Group (VTOL) Reports Q2 Results Tomorrow

Bristow Group (VTOL), a helicopter services provider, is set to report its Q2 earnings tomorrow after market hours. Analysts anticipate an 8.4% year-on-year revenue growth, building on a previous quarter where the company beat revenue expectations but missed EBITDA and EPS estimates. Investor sentiment …

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

Briscoe grows sales for third consecutive quarter

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

Q3 2025 Bristow Group Inc Earnings Call Transcript

This article provides the Q3 2025 earnings call transcript for Bristow Group Inc. (FRA:ERG1), highlighting their strong financial performance with adjusted EBITDA of $67.1 million and a positive outlook for offshore energy and government services. Despite facing challenges like supply chain issues and increased …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

Bristol-Myers Squibb Company supera las previsiones de los analistas: descubre cuáles son las previsiones de consenso para este año

Briscoe Group Posts Modest H1 Sales Growth as Sporting Goods Outpace Homewares

Briscoe Group Limited Provides Earnings Guidance for the Six Months Ended July 26, 2026

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Enterprise value to revenue forward of Bristow Group, Inc. – NYSE:VTOL

This article displays the "Enterprise value to revenue forward" metric for Bristow Group, Inc. (NYSE: VTOL) on TradingView. It indicates that the market is closed and there are no current trades for the stock. The content is primarily a data display page with various …

Bristol-Myers Squibb Company : Consenso de Precios Objetivo y Recomendaciones de los Analistas | BMY | US1101221083

Guggenheim eleva el precio objetivo de Bristol-Myers Squibb a 75 dólares

Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus

Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk

Bristow Group declares quarterly dividend of $0.125 per share By Investing.com

Bristow Group Inc. (VTOL) has announced a quarterly cash dividend of $0.125 per share, payable on August 28, 2026, to shareholders of record as of August 14, 2026. The company, which provides aviation services globally, intends to continue paying regular quarterly dividends, with future …

Bristow Group Sets Aug. 28 Payment Date for Cash Dividend

Bristow Group (NYSE: VTOL) has declared a quarterly cash dividend of $0.125 per share of common stock. The dividend will be paid on August 28, 2026, to shareholders of record as of August 14, 2026. The company currently intends to continue paying regular quarterly …

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …